AstraZeneca PLC is a Swedish-British multinational pharmaceutical and biotechnology company headquartered at the Cambridge Biomedical Campus in the United Kingdom. Formed in 1999 through the merger of... AstraZeneca PLC is a Swedish-British multinational pharmaceutical and biotechnology company headquartered at the Cambridge Biomedical Campus in the United Kingdom. Formed in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group, it develops, manufactures, and commercializes innovative prescription medicines addressing major global health challenges. The company's robust portfolio spans key therapeutic areas including **oncology**, where it advances next-generation cancer treatments; **cardiovascular, renal, and metabolic diseases**; **respiratory and immunology**, targeting asthma, COPD, and immune-driven conditions; as well as rare diseases, neuroscience, infection, and inflammation. Notable products include Nexium for gastrointestinal issues, Tagrisso for lung cancer, and contributions to COVID-19 vaccines. With major R&D hubs in Cambridge, Gothenburg, and Gaithersburg, AstraZeneca employs around 90,000 people across 85 countries, driving scientific breakthroughs through strategic acquisitions like MedImmune and partnerships. Its global operations emphasize patient-centric innovation, sustainability, and access initiatives such as Healthy Heart Africa, solidifying its role as a leader in biopharmaceuticals.
In 2024, AstraZeneca was subject to the Corporate Sustainability Reporting Directive (CSRD)'s requirements, which mandated the company to publish EU Taxonomy disclosures.
The company reported the eligibility and alignment of Turnover, Capital Expenditure (CAPEX) and Operating Expenditure (OPEX) with the EU Taxonomy, helping assess the extent to which its business activities align with Europe's environmental sustainability goals.
AstraZeneca has also provided an activity-level breakdown of its EU Taxonomy disclosures. This granular reporting enhances transparency around which economic activities of AstraZeneca are considered environmentally sustainable and contribute to at least one of the six environmental objectives defined under the EU Taxonomy framework.
Metric (tonnes)
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned A1 Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
b
0000000
Total Taxonomy Eligible A Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
b
0000000
Total Taxonomy Non-Eligible B Turnover
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
b
0000000
Metric (tonnes)
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned A1 Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
b
0000000
Total Taxonomy Eligible A Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
b
0000000
Total Taxonomy Non-Eligible B Opex
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
b
0000000
Metric (tonnes)
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned A1 Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
b
0000000
Total Taxonomy Eligible A Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
b
0000000
Total Taxonomy Non-Eligible B Capex
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
b
0000000
3.2 CE - Renovation of existing buildings, 7.2 CCM/CCA - Renovation of existing buildings
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Limited Data Preview
You are viewing a limited preview of AstraZeneca’s EU Taxonomy dataset. The full dataset, available for download, includes eligibility and alignment metrics for turnover, CAPEX, and OPEX across all EU Taxonomy categories (A1, A2, A, B, and A+B), at both aggregate and activity level, with historical coverage back to 2021.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Used by 1,000+ teams in finance, climate, and research
Verified Sources Behind AstraZeneca’s EU Taxonomy Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore AstraZeneca’s data sources below and access millions more through our Disclosure Search.
a. AstraZeneca's Annual Report 2024
b. AstraZeneca's Annual Report 2023
c. AstraZeneca's Annual Report 2022
Insights into AstraZeneca's Revenues from Sustainable Activities
In 2024, AstraZeneca reported EU Taxonomy-eligible revenues of USD 51.86 billion, representing 96% of its total turnover. Of this amount, USD 0 of AstraZeneca's revenues was classified as EU Taxonomy-aligned, indicating that 0% of the revenue-generating activities undertaken by the company substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Insights into AstraZeneca's CAPEX from Sustainable Activities
In 2024, AstraZeneca reported EU Taxonomy-eligible CAPEX of USD 6.78 billion,representing 88% of its total CAPEX. Of this amount, USD 137.00 million of AstraZeneca's CAPEX was classified as EU Taxonomy-aligned, indicating that 2% of the company's investments were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
How much of AstraZeneca's capital expenditure (CAPEX) is eligible under the EU Taxonomy?
In 2024, AstraZeneca reported that USD 6.78 billion of its capital expenditure (CAPEX) was eligible under the EU Taxonomy, representing 88% of the company's total CAPEX. Of this amount, USD 137.00 million (2% of total CAPEX) was classified as Taxonomy-aligned. This means that 86% of AstraZeneca's CAPEX is eligible but not aligned, indicating that these investments either did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards (MSS).a
How much of AstraZeneca's eligible CAPEX is aligned with the EU Taxonomy?
In 2024, AstraZeneca reported that USD 137.00 million of its CAPEX was aligned under the EU Taxonomy, representing 2% of its total capital investment.a
This low alignment reflects that AstraZeneca is beginning to transition its capital allocation toward greener investments, but still retains substantial opportunities for further alignment with sustainability goals.
AstraZeneca's Eligibility & Alignment Overview
AstraZeneca's Contribution to Environmental Objectives
Total Taxonomy Aligned A1 Capex
Total Taxonomy Eligible but Not Aligned A2 Capex
How is AstraZeneca's taxonomy-aligned CAPEX distributed across the EU environmental objectives?
In 2024, AstraZeneca reported that its taxonomy-aligned capital expenditure (CAPEX) was distributed across the following EU environmental objectivesa:
Climate Change Mitigation: 2%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 0%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much AstraZeneca is investing in climate-related solutions?
In 2024, AstraZeneca allocated USD 155.10 million of its CAPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 2% of the company's total capital expenditure,indicating that AstraZenecahas only marginally directed its capital expenditure toward climate-related activities, suggesting limited alignment with climate objectives.a
Insights into AstraZeneca's OPEX from Sustainable Activities
In 2024, AstraZeneca reported EU Taxonomy-eligible OPEX of USD 2.56 billion,representing 18% of its total operating expenses (OPEX). Of this amount, USD 0 of AstraZeneca's OPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's operating expenses were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Want Full Access to AstraZeneca's EU Taxonomy Dataset?
b
b
a
b
b
a
b
b
b
b
a
b
b